Privium Fund Management B.V. Has $1.35 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Privium Fund Management B.V. reduced its holdings in Krystal Biotech by 18.8% in the first quarter, selling 1,740 shares and now holds 7,510 shares worth approximately $1.35 million.
• Several other institutional investors have increased their stakes in Krystal Biotech, including Fifth Third Bancorp, which boosted its investment by 159.1%.
• Krystal Biotech's stock has a market capitalization of $4.54 billion and recently opened at $156.98, with a 52-week range between $122.80 and $207.84.

Privium Fund Management B.V. lessened its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 18.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,510 shares of the company's stock after selling 1,740 shares during the period. Krystal Biotech comprises approximately 0.4% of Privium Fund Management B.V.'s holdings, making the stock its 28th biggest holding. Privium Fund Management B.V.'s holdings in Krystal Biotech were worth $1,354,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in KRYS. Fifth Third Bancorp grew its position in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after buying an additional 105 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech during the 4th quarter valued at about $95,000. Covestor Ltd grew its position in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after buying an additional 642 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after buying an additional 432 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Krystal Biotech during the 1st quarter valued at about $223,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Trading Down 14.0%

KRYS stock traded down $22.04 during trading on Monday, hitting $134.94. 2,112,276 shares of the stock traded hands, compared to its average volume of 308,304. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of 34.96 and a beta of 0.70. The company has a 50 day simple moving average of $140.83 and a 200 day simple moving average of $155.89.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KRYS has been the subject of several recent analyst reports. Bank of America decreased their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Citigroup restated a "neutral" rating and issued a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. Guggenheim decreased their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Chardan Capital restated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. Finally, HC Wainwright restated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $211.33.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 49,800 shares of company stock worth $7,487,943 in the last ninety days. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).